Extendicare reported quarterly earnings per share of C$0.41, above the C$0.36 estimate. The result extends a recent run of meeting or beating estimates. But the supplied data does not include actual revenue or margins.
Extendicare Inc. (TSX: EXE) reported results after the market closed on November 5 for the quarter ended September 30, 2026. Its C$0.41 EPS was 13.9% above the estimate. The company has met or beaten estimates in three of its last four comparable quarters. For Canadian investors, that’s a useful snapshot, but not a full picture of operating performance: the supplied results include no actual revenue, margins, or management commentary. See the Extendicare stock page for company metrics and coverage.
Recent earnings trend
Extendicare Inc
EXE.TO
EXE.TO
Extendicare Inc
WealthAwesomeMarket cap
$2.62B
P/E
20.3x
Div. yield
0.46%
Div. / share
$0.13
52W high
$38.92
52W low
$15.50
1W change
+3.91%
Beta
1.08
Analyst Price Targets
Based on analyst covering EXE · as of Oct 23, 2026
Wall Street analysts forecast EXE stock price to rise 41.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$38.94
+41.1% Upside
Previously C$39.83 on Sep 17, 2026
Current Price
C$27.61
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EXE's historical volatility
30-Day Vol
36.3%
Annualized
90-Day Vol
32.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$23.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$26.01 | C$22.95 – C$29.48 |
| 60 trading days | C$24.51 | C$20.54 – C$29.26 |
| 90 trading days | C$23.09 | C$18.59 – C$28.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-02-25 | — | 0.3700 | — |
| 2026-09-30 | 2026-11-05 | 0.4100 | 0.3600 | +13.9% |
| 2026-06-30 | 2026-08-06 | 0.3900 | 0.3900 | +0.0% |
| 2026-03-31 | 2026-05-07 | 0.4200 | 0.2100 | +100.0% |
| 2025-06-30 | 2025-08-06 | 0.3732 | — | — |
| 2025-03-31 | 2025-05-06 | 0.1759 | — | — |
Investor takeaway: Extendicare beat the EPS estimate, continuing a generally positive recent trend. Still, the headline result doesn’t prove that underlying operations improved. Investors need revenue, margin, and cash-flow details to assess that. EXE closed at C$27.61 in the supplied market data, below its 50-day and 200-day moving averages. Analyst targets are higher, while the Wealth Awesome statistical model projects a lower 90-day average. These are different reference points, not guarantees or investment advice.
C$0.41 EPS, 13.9% above estimate
Extendicare reported EPS of C$0.41, C$0.05 above the C$0.36 estimate for the quarter ended September 30, 2026. It has now beaten estimates in three of its last four comparable reported quarters. Actual revenue and margins weren’t provided, so investors should consider the EPS surprise alongside fuller operating results when they become available.
Bull case
Extendicare’s C$0.41 EPS beat the C$0.36 estimate, and the company has beaten estimates in three of its last four comparable quarters. The supplied data puts next-quarter EPS at C$0.39 and revenue at C$581.2 million, with estimated revenue growth of 32.0%. These figures offer a benchmark for the next report, but they’re based on one analyst, not a company forecast. The average analyst target of C$38.94 is also well above the last close of C$27.61.
Bear case
The EPS beat leaves key questions unanswered because the supplied data doesn’t include actual revenue or margins. The next-quarter estimates come from one analyst, so they don’t represent a broad market view. In the supplied snapshot, EXE shares were below their 50-day and 200-day moving averages. The Wealth Awesome 90-day model also puts its average below the current price. The model isn’t investment advice, but it shows that an earnings beat doesn’t remove uncertainty about the share price or the company’s operations.
Analysis
Extendicare reported EPS of C$0.41 for the quarter ended September 30, 2026, compared with the calendar estimate of C$0.36. That’s a difference of C$0.05 per share, or a 13.89% positive surprise. The company reported results after the market closed on November 5. The supplied earnings data doesn’t include actual revenue, margins, or other operating measures, so EPS alone can’t explain what drove the difference. The recent earnings trend table and chart provide more history. The main takeaway is that Extendicare beat estimates in three of its last four comparable reported quarters.
Analysis
The supplied next-quarter estimates are C$0.39 EPS and C$581.20 million in revenue, with estimated revenue growth of 32.0%. Both estimates come from one analyst, so treat them as a limited benchmark rather than a broad consensus. The EPS estimate was revised from no figure 30 days ago to C$0.39 now. The data shows no upward or downward revisions during that period. Follow results and company metrics on the Extendicare stock page.
Analysis
The supplied analyst-target data lists an average target of C$38.94, compared with the last close of C$27.61. That implies 41.1% upside to the average target. The source calls the consensus bullish based on this comparison, but a formal rating isn’t available for Canadian listings. The target is a reference point, not a promised return.
Separately, the Wealth Awesome statistical 90-day price model gives an average of C$23.09. Its 68% range is C$18.59 to C$28.69, and its 95% range is C$14.97 to C$35.63. The model’s annualized drift is -50.0%, based on its inputs and recent volatility. It’s statistical, not financial advice. The analyst target details and the model are separate tools, and neither replaces an assessment of Extendicare’s operating results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
